U.S. Markets closed

Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
174.07+3.22 (+1.88%)
At close: 4:00PM EDT

174.11 0.04 (0.02%)
After hours: 4:33PM EDT

People also watch
BIIBGILDCELGMRKBMY
Full screen
Previous Close170.85
Open171.42
Bid174.07 x 200
Ask174.11 x 300
Day's Range170.83 - 174.54
52 Week Range133.64 - 184.21
Volume2,884,038
Avg. Volume3,476,170
Market Cap128.01B
Beta1.76
PE Ratio (TTM)16.53
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.65%)
Ex-Dividend Date2017-05-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia4 hours ago

    July's Tough, but These Stocks Tend to Do Well

    July isn't a great month for the stock market historically, but these stocks tend to perform well.

  • The Wall Street Journal4 hours ago

    [$$] HGGC Backs Provider of Data-Visualization Software

    Denodo Technologies Inc.’s founder and senior management team will retain an ownership stake in the company.

  • Barrons.com5 hours ago

    Amgen: Now or Later?

    In biotech, investors are always looking for the next big thing, or at least the next thing. Which is one reason Amgen's (AMGN) Erenumab is being closely watched by analysts. Amgen submitted the data for the treatment of migraines by erenumab to the FDA in May. And Oppenheimer's Leah Rush Cann, who rates Amgen Outperform, argues that Erenumab will "be adopted for treatment of migraine quickly after launch." She explains why: Our report Migraine Survey, June 27, 2017, supports our view that Erenumab will be adopted for treatment of migraine quickly after launch.